
Feb 24 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON: DB-OTO RESULTS SHOW CLINICALLY MEANINGFUL HEARING IMPROVEMENTS IN NEARLY ALL CHILDREN WITH PROFOUND GENETIC HEARING LOSS IN CHORD TRIAL
REGENERON: 10 OF 11 CHILDREN WITH AT LEAST ONE POST-TREATMENT ASSESSMENT SHOWED NOTABLE IMPROVEMENTS IN HEARING IN PHASE 1/2 CHORD TRIAL
REGENERON: 72-WEEK RESULTS FOR DB-OTO SHOWS SPEECH AND DEVELOPMENT PROGRESS IN FIRST CHILD DOSED AT 10 MONTHS OF AGE
Source text: [ID:]
Further company coverage: REGN.O